- Home
- HOFT vs CHRS Comparison
HOFT vs CHRS Comparison
Compare HOFT & CHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HOFT
- CHRS
- Stock Information
- Founded
- HOFT 1924
- CHRS 2010
- Country
- HOFT United States
- CHRS United States
- Employees
- HOFT N/A
- CHRS N/A
- Industry
- HOFT Home Furnishings
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- HOFT Consumer Discretionary
- CHRS Health Care
- Exchange
- HOFT Nasdaq
- CHRS Nasdaq
- Market Cap
- HOFT 119.9M
- CHRS 112.5M
- IPO Year
- HOFT 1999
- CHRS 2014
- Fundamental
- Price
- HOFT $9.95
- CHRS $0.76
- Analyst Decision
- HOFT
- CHRS Buy
- Analyst Count
- HOFT 0
- CHRS 3
- Target Price
- HOFT N/A
- CHRS $4.68
- AVG Volume (30 Days)
- HOFT 89.9K
- CHRS 1.2M
- Earning Date
- HOFT 06-12-2025
- CHRS 08-07-2025
- Dividend Yield
- HOFT 9.25%
- CHRS N/A
- EPS Growth
- HOFT N/A
- CHRS N/A
- EPS
- HOFT N/A
- CHRS N/A
- Revenue
- HOFT $389,210,000.00
- CHRS $272,251,000.00
- Revenue This Year
- HOFT $1.35
- CHRS N/A
- Revenue Next Year
- HOFT $10.05
- CHRS $132.69
- P/E Ratio
- HOFT N/A
- CHRS $1.75
- Revenue Growth
- HOFT N/A
- CHRS 19.87
- 52 Week Low
- HOFT $7.34
- CHRS $0.66
- 52 Week High
- HOFT $19.79
- CHRS $2.43
- Technical
- Relative Strength Index (RSI)
- HOFT 47.17
- CHRS 40.60
- Support Level
- HOFT $9.68
- CHRS $0.74
- Resistance Level
- HOFT $10.50
- CHRS $0.79
- Average True Range (ATR)
- HOFT 0.79
- CHRS 0.05
- MACD
- HOFT -0.12
- CHRS 0.00
- Stochastic Oscillator
- HOFT 16.79
- CHRS 12.76
About HOFT Hooker Furnishings Corporation
Hooker Furnishings Corp is a designer, marketer and importer of casegoods (wooden and metal furniture), leather furniture, fabric-upholstered furniture, lighting, accessories, and home decor for the residential, hospitality and contract markets. It is also domestically manufactured premium residential custom leather, custom fabric-upholstered furniture, and outdoor furniture. The company operates in four segment Hooker Branded segment, Home Meridian segment, Domestic Upholstery segment and All Other.
About CHRS Coherus BioSciences Inc.
Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.